Have a personal or library account? Click to login
Relationship between sex hormones levels and 18F-FDG uptake by the ovaries in premenopausal woman Cover

Relationship between sex hormones levels and 18F-FDG uptake by the ovaries in premenopausal woman

Open Access
|Sep 2019

Figures & Tables

Figure 1

Ovarian 18F-FDG uptake according to the number of weeks since the onset of menstruation. (A) The ovarian maximum standardized uptake value (SUVmax) was highest at 2 weeks after the onset of menstruation and lowest during the first week after menstruation. The ovarian SUVmax at weeks 3 and 4 was between that for the first and second weeks. (B) Comparisons of ovarian SUVmean showed a trend similar to that of SUVmax.
Ovarian 18F-FDG uptake according to the number of weeks since the onset of menstruation. (A) The ovarian maximum standardized uptake value (SUVmax) was highest at 2 weeks after the onset of menstruation and lowest during the first week after menstruation. The ovarian SUVmax at weeks 3 and 4 was between that for the first and second weeks. (B) Comparisons of ovarian SUVmean showed a trend similar to that of SUVmax.

Figure 2

Scatter diagrams of the relationship between progesterone level and ovarian 18F-FDG uptake in all subjects. (A) Progesterone levels were weakly correlated with ovarian SUVmax (p < 0.001, rho = 0.28). (B) A weakly positive correlation was also detected between progesterone level and ovarian SUVmean (p < 0.001, rho = 0.30).
Scatter diagrams of the relationship between progesterone level and ovarian 18F-FDG uptake in all subjects. (A) Progesterone levels were weakly correlated with ovarian SUVmax (p < 0.001, rho = 0.28). (B) A weakly positive correlation was also detected between progesterone level and ovarian SUVmean (p < 0.001, rho = 0.30).

Correlation between ovarian 18F-FDG uptake and sex hormone levels

Parameters Follicular phase (n = 100)Luteal phase (n = 97)Total (N = 197)
Spearman’s rho (95% CI)p-valueSpearman’s rho (95% CI)p-valueSpearman’s rho (95% CI)p-value
Age −0.15 (−0.34–0.04)0.125−0.06 (−0.26–0.13)0.500−0.14(−0.27–0.01)0.051
Estradiol ProgesteroneCorrelation with0.12 (−0.07–0.30) 0.29 (0.09–0.45)0.235 0.003*−0.03 (−0.23–0.16) 0.13 (−0.07–0.32)0.721 0.1310.05 (−0.08–0.19) 0.28 (0.14–0.40)0.426 <0.001*
TestosteroneSUVmax ovary of−0.08 (−0.27–0.12)0.4280.13 (−0.07–0.32)0.1290.03 (−0.11–0.17)0.669
FSH -0.18 (−0.37 to −0.01)0.0820.18 (−0.10–0.43)0.200−0.10 (−0.16 to −0.04)0.174
LH 0.07 (−0.24–0.38)0.657−0.01 (−0.28–0.27)0.973−0.02 (−0.24–0.18)0.792
Age −0.14 (−0.32–0.05)0.164−0.10 (−0.29–0.09)0.318−0.15 (−0.28–0.01)0.035*
Estradiol 0.09 (−0.09–0.29)0.324−0.06 (−0.26–0.13)0.5320.03 (−0.10–0.17)0.601
ProgesteroneCorrelation with0.29 (0.09–0.46)0.003*0.16 (−0.04–0.35)0.1610.30 (0.17–0.42)<0.001*
TestosteroneSUVmean ovary of−0.13 (-0.31–0.06)0.1970.13 (−0.06–0.32)0.1930.01 (−0.12–0.15)0.840
FSH −0.16 (−0.33–0.07)0.1220.20 (−0.08–0.45)0.154−0.13 (−0.18 to −0.05)0.116
LH −0.67 (−0.39–0.27)0.7000.01 (−0.27–0.29)0.954−0.04 (−0.25–0.17)0.690

Patient characteristics

Menstrual phase on test day
Follicular phaseLuteal phaseTotalp-value
Number of patients, n (%)100 (50.8)97 (49.2)197 (100)
Age, years45 (42–47)44 (38–47)44 (40–47)0.150
Sex hormone levels
Estradiol, pg/ml125 (76–176)150 (84–182)126 (81–179)0.292
Progesterone, ng/ml1.62 (1.26–2.53)12.30 (3.85–18.95)2.71 (1.42–12.11)< 0.001*
Testosterone, ng/ml0.34 (0.21–0.52)0.37 (0.23–0.51)0.36 (0.23–0.51)0.342
FSH, mIU/ml5.7 (3.9–8.1)2.9 (1.7–4.1)3.7 (2.4–6.1)< 0.001*
LH, mIU/ml5.9 (2.9–8.6)3.6 (2.5–6.6)4.6 (2.7–7.8)0.105
SUVmax of ovary1.70 (0–2.70)2.10 (1.50–3.63)2.00 (0–3.23)0.030*
SUVmean of ovary1.30 (0-1.85)1.60 (0.9–2.40)1.40 (0–2.10)0.015*
DOI: https://doi.org/10.2478/raon-2019-0035 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 293 - 299
Submitted on: Apr 30, 2019
|
Accepted on: Jul 17, 2019
|
Published on: Sep 24, 2019
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2019 Tae Hee Kim, Mi Ran Kim, Yongsik Jung, Young-Sil An, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.